The EVP & Chief Tech Ops Officer of Ultragenyx Pharmaceutical (NASDAQ: RARE) is Selling Shares

Yesterday, the EVP & Chief Tech Ops Officer of Ultragenyx Pharmaceutical (RAREResearch Report), Dennis Karl Huang, sold shares of RARE for $23.06K.

In addition to Dennis Karl Huang, 10 other RARE executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Ultragenyx Pharmaceutical’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $61.71 million and quarterly net profit of $25.32 million. In comparison, last year the company earned revenue of $24.15 million and had a GAAP net loss of $99.17 million. The company has a one-year high of $99.25 and a one-year low of $31.99. Currently, Ultragenyx Pharmaceutical has an average volume of 487.99K.

Based on 7 analyst ratings, the analyst consensus is Strong Buy with an average price target of $90.57, reflecting a 1.7% upside.

The insider sentiment on Ultragenyx Pharmaceutical has been negative according to 101 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.